| 25 | Antibody-Cytokine hu14.18-IL2
Retains Antibody and IL-2 Activity Following Clinical Administration
and Induces IL-2- Mediated Immune Activation Hank JA¹, Albertini MR¹, Gan J¹, Surfus J¹, King D¹, Schalch H¹, Kim K¹, Dahl T4, Kashala O4, Sturmhoefel K4, Reisfeld RA², Gillies SD³, Sondel PM¹ ¹The University of Wisconsin Comprehensive Cancer Center-Madison WI; ²The Scripps Research Institute-La Jolla CA; ³Lexigen Pharmaceuticals-Lexington MA; and 4EMD Pharmaceuticals-Durham NC |
| 26 |
Vaccination of prostate cancer patients
with prostate specific antigen and biological adjuvants reduces
serum PSA Head JF, Jiang XP, Elliott RL Mastology Research Institute of the Elliott Hailey Head Breast Cancer Research and Treatment Center, Baton Rouge, LA |
| 28 | Sequential Photon or Neutron Radiation
and Interleukin-2 for Prostate Carcinoma Bone Tumors in an Experimental
Model Hillman GG, Maughan RL, Grignon DJ, Che M, Yudelev M, Wang Y, Layer A, Wright JL, and Forman JD. Departments of Radiation Oncology and Pathology, Karmanos Cancer Institute at Wayne State University. Detroit, MI |
| 29 | Administration of
either anit-CD40 or interleukin-12 following lethal total body
irradiation induces an acute lethal toxicity affecting the gut Hixon JA¹, Wigginton JM², Wiltrout RH³, Blazar BR4, Anver MR5, Murphy WJ1 ¹Intramural Research Support Program, Science Applications International Corporation (SAIC)-Frederick, Maryland; ²Investigational Biologics Group, National Cancer Institute-Frederick, MD; ³Laboratory of Experimental Immuology, National Cancer Institute-Frederick, MD; 4Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, MN; 5Pathology Histotechnology Laboratory, SAIC-Frederick, MD |
| 30 | Molecular Mechanism for IL-2 Plus
IL-12 Regulation of Interferon-Gamma mRNA in Human NK cells Hodge, Deborah L.¹, Martinez, Alfredo³, Julias, John G.², Taylor, Lynn S.¹ and Young, Howard A.¹ ¹Laboratory of Experimental Immunology, ²HIV Drug Resistance Program, NCI-CCR at Frederick, Frederick, MD; ³Dept. Cell and Cancer Biology, NCI, Bethesda, MD |
| 31 | Non-Myeloablative Allogeneic Stem
Cell Transplantation for Metastatic Renal Cell Carcinoma: the
University of Chicago Experience Hu HS¹, Rini BI², Zimmerman TM¹, Gajewski TF¹, Stadler WM¹, Vogelzang NJ1 ¹University of Chicago, Chicago, IL; ²University of California at San Francisco, San Francisco, CA |
| 32 | Improving Vaccine Potency Through
Intercellular Spreading and Enhanced MHC Class I Presentation
of Antigen Chien-Fu Hung, Wen-Fang Cheng, Liangmei He, Morris Ling, and T.-C. Wu Pathology, Johns Hopkins University Baltimore, MD |
| 33 | Anti-tumour effect of recombinant
mycobacteria genetically engineered to secrete interleukin-15
and tumour necrosis factor Young, S¹, Murphy, M¹, Xhu, X¹, O’Donnell, MA², Selby, P¹, James, K³, Jackson AM1 ¹Applied Immunology Group, Imperial Cancer Research Fund, Leeds, United Kingdom; ²Dept Urology, Iowa University, IA; ³Dept Surgery, University of Edinburgh, United Kingdom |
| 34 | T9 Glioma Cells Expressing Membrane
Macrophage Colony Stimulating Factor (mM-CSF) Produce CD4+ Mediated
Protective Immunity Against T9 Intracranial Gliomas and Systemic
Immunity Against Different Syngeneic Gliomas Jadus MR, Sanchez R, Williams CC, Daza JL, Dan Q, Xu Q, Chen Y, Delgado C, Arpajirakul N, Jeffes EWB, Kim RC, Wepsic HT Diagnostic & Molecular Health Care Group, Veterans Affairs Medical Center, Long Beach, CA and Pathology Department, University of California, Irvine, CA |
